The Role of Tranexamic Acid in Aesthetic Plastic Surgery: A Survey of the British Association of Aesthetic Plastic Surgeons

Wokes, James; Erdmann, Matthias; McLean, N.R.

doi:10.1093/asj/sjaa149

Cited by 22 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[63][64][65][66][67] A similar economic benefit has been demonstrated in other surgical specialties as well as in trauma medicine. [68][69][70] This financial advantage may be more pronounced in low resource environments, where the costs associated blood transfusion can be significantly greater than in developed countries, both due to decreased availability of blood products and the higher risk of bloodborne infections. 71 We also found that rates of VTE did not increase significantly with TXA administration.…”

Section: Discussionmentioning

confidence: 99%

The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis

Kim

Alrumaih

Donnelly

et al. 2023

CUAJ

View full text Add to dashboard Cite

Introduction: Tranexamic acid (TXA) is an antifibrinolytic agent widely used in surgery to decrease bleeding and reduce the need for blood product transfusion. The role of TXA in urology is not well summarized. We conducted a systematic review of studies reporting outcomes of TXA use in urological surgery. Methods: A comprehensive search was conducted from the following databases: PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers performed title and abstract screening, full text review, and data collection. Primary outcomes included estimated blood loss (EBL), decrease in hemoglobin, decrease in hematocrit, and blood transfusion rates. Secondary outcomes included TXA administration characteristics, length of stay, operative time, and postoperative thromboembolic events. Results: A total of 26 studies consisting of 3201 patients were included in the final analysis. These included 11 studies on percutaneous nephrolithotomy, 10 on transurethral resection of the prostate, three on prostatectomy, and one on cystectomy. Estimated blood loss (EBL), transfusion rate, hemoglobin drop, operative time, and length of stay were significantly improved with TXA administration. In addition, the use of TXA was not associated with an increased risk of venous thromboembolism (VTE). The route, dosage, and timing of TXA administration varied considerably between included studies. Conclusions: TXA use may improve blood loss, transfusion rates, and perioperative parameters in urological procedures. In addition, there is no increased risk of VTE associated with TXA use in urological surgery; however, there is still a need to determine the most effective TXA administration route and dose. This review provides evidence-based data for decision-making in urological surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis

Kim

Alrumaih

Donnelly

et al. 2023

CUAJ

View full text Add to dashboard Cite

show abstract

“…Because of the potential benefits of reduced bleeding, postoperative edema, ecchymosis, and drain requirements, the role of TXA has been gradually expanding in plastic surgery 20,30,31 . Although initially introduced in craniofacial procedures, it has recently been incorporated into breast and aesthetic procedures, including reduction mammaplasty 17,18,22,29 .…”

Section: Discussionmentioning

confidence: 99%

The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates

Marxen

Kebede

et al. 2022

Ann Plast Surg

View full text Add to dashboard Cite

Background: Bleeding complications are not uncommon after breast reduction surgery, and recently, tranexamic acid (TXA) as an antifibrinolytic agent has been used in various surgical specialties as a way to minimizes such adverse outcomes. We elected to evaluate the effectiveness of intravenous (IV) intraoperative TXA in reduction mammoplasty patients. Methods: This is a retrospective chart review of clinical charts of all patients who received reduction mammoplasty by a single surgeon at Emory University Hospital or its affiliated Aesthetic Center from January 1, 2020, to March 1, 2022. Seventy-four consecutive breast reduction patients received 1-g IV TXA intraoperatively compared with 117 consecutive controls. The outcome of interest included 30-day postoperative bleeding complications. Results: There was no significant difference in age (P = 0.92), body mass index (P = 0.98), percentage of smokers (P = 0.56), operating time (P = 0.87), estimated blood loss (P = 0.90), or weight removed (P = 0.98) between patients in each arm. There were 19 bleeding events (16.2%) in the non-TXA arm compared with 1 bleeding event (1.4%) in the TXA arm (P = 0.0143). Of the 19, 6 (5.1%) were major events, and 13 were minor events (11.1%); the only bleeding event in the TXA arm was minor. Number needed to treat all bleeding events with use of TXA was 7, and the number needed to treat minor hematomas was 11. There was no significant difference in the rate of seroma, wound healing complications, infection, or nipple necrosis between the 2 arms (P > 0.05). Conclusions: The use of IV TXA is a safe and effective way to reduce hematoma rates in patients receiving reduction mammoplasty.

show abstract

“…13 Tranexamic acid, by inhibiting plasminogen, acts as an anti-inflammatory agent minimizing postoperative seroma formation, swelling, and bruising which leads to a reduced downtime thus making a very big impact in facial aesthetic surgeries. 14 Tranexamic acid has been safely administrated postoperatively to reduce healing time and minimize bleeding complications of bleeding such as bruising. It is used topically during tooth extraction, orthopedic procedures, cardiac surgery, and other surgical procedures.…”

Section: Discussionmentioning

confidence: 99%

Postoperative Ecchymosis in Upper Blepharoplasty: A Split Face Study of Tranexamic Acid Versus Etamsylate

et al. 2021

View full text Add to dashboard Cite

Objective: To compare the efficacy of tranexamic acid (TXA) versus etamsylate (ETM) in reducing postoperative ecchymosis in upper blepharoplasty. Introduction: With an increase in demand for shortened recoveries after facial aesthetic surgery, various optional approaches have been sought out. In terms of ecchymosis, TXA and ETM have been most commonly used. Method: A prospective, intrapatient split face study was conducted from January 2020 to January 2021 in 40 patients who underwent upper blepharoplasty under local anesthesia. Two equal anesthetic solutions were prepared; Solution A contained TXA and solution B contained ETM. Solution A was injected in the right eyelid and solution B in the left eyelid. Postoperative ecchymosis was assessed by 2 blinded evaluators, the assisting surgeon (Observer 1) and an external surgeon (Observer 2) at 48 h and on the seventh day using a scale published by Sagiv et al. Results: Postoperative ecchymosis was found to be less at 48 h by both observers with TXA solution. Moreover, at the seventh day, no ecchymosis was found in 32.5% with TXA solution compared to 2.5% with ETM solution. Kappa analysis showed concordance between observers. Conclusion: In our study, TXA solution was a more effective therapy when compared to ETM solution for reducing ecchymosis. Larger case studies are required to prove the difference for validation.

show abstract

The Role of Tranexamic Acid in Aesthetic Plastic Surgery: A Survey of the British Association of Aesthetic Plastic Surgeons

Cited by 22 publications

References 33 publications

The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis

The impact of tranexamic acid on perioperative outcomes in urological surgeries: A systematic review and meta-analysis

The Usage of Intravenous Tranexamic Acid in Reduction Mammaplasty Safely Reduces Hematoma Rates

Postoperative Ecchymosis in Upper Blepharoplasty: A Split Face Study of Tranexamic Acid Versus Etamsylate

Contact Info

Product

Resources

About